![Alexion snares OK for quicker-infusing Ultomiris formula—and a subQ version is on the horizon | Fierce Pharma Alexion snares OK for quicker-infusing Ultomiris formula—and a subQ version is on the horizon | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1602823967/Ultomiris%20100%20mg%3Aml%20%E2%80%94%20Alexion%20Pharmaceuticals.jpg?VersionId=xnx44ZOfBgmkjGvC89uEvz4Onqnxsfrg)
Alexion snares OK for quicker-infusing Ultomiris formula—and a subQ version is on the horizon | Fierce Pharma
![SciELO - Saúde Pública - The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health SciELO - Saúde Pública - The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health](https://scielosp.org/media/assets/rsp/v54/1518-8787-rsp-54-22-gf03.jpg)
SciELO - Saúde Pública - The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health
What would be the cost of soliris (world's most expensive drug) after it goes off the patent in 2019? Present cost 500,000 $ per year. - Quora
![The cost–effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting The cost–effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting](https://becarispublishing.com/cms/10.2217/cer-2022-0076/asset/1006c8fa-f08a-4f6b-9a87-033b6589cbaf/assets/images/large/figure2.jpg)
The cost–effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting
![Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands | SpringerLink Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10198-022-01556-5/MediaObjects/10198_2022_1556_Fig1_HTML.png)